S2 Table. Summary of the results of the 13 studies on the nutritional status of nocturnal hemodialysis patients.

Author	Results of biochemical measurements on nutrition	Results of body composition	Results of food records	Conclusion of the authors	Comments
Alloatti, 2002	PCR: g/day, CHD baseline 1.12 (0.30), after ≥ 6 months NHD 1.20 (0.33) Serum albumin: g/L, CHD baseline 38.5 (6.0), after ≥ 6 months NHD 39.8 (6.0)	Post-dialysis weight: kg, CHD baseline 68.5 (9.6), after ≥6 months NHD 70.8 (10.7); P<0.01		Good results of: toxin removal, water balance regulation, and maintenance of an adequate nutritional status.	Second measurement is after 6 months NHD, not clear whether it is 6 or 36 months.
Cravedi, 2009	nPCR: g/kg/day CHD, baseline 0.9 (0.3), 6 months 0.9 (0.3), 12 months 1.0 (0.4), NHD, 18 months 0.9 (0.3), 24 months 1.1 (0.3), 30 months 1.1 (0.3), 36 months 1.1 (0.4)	Post-dialysis body weight: kg, CHD baseline (at 12 months) 61,4 (21.8), NHD 6 months (at 18 months) 61.8 (14.5), NHD 12 months (at 24 months) 63.4 (15.8), p<0.001 (measured from Fig. 1.B of the original article)		Improvement of nutritional status.	Results of body weight were shown in a figure. Only. Results were measured manually from the figure
David, 2009	Albumin: g/L, baseline 42.8 (2.6), 3 months 43.3 (1.6), 6 months 43.6 (2.6), 9 months 43.2 (3.1), 12 months 44.4 (2.5), ns nPCR: g/kg/day, baseline 1.39 (0.29), 3 months 1.71 (0.23) [1], 6 months 1.55 (0.38), 9 months 1.78 (0.37) [1], 12 months 2.25 (1.5), ns CRP: mg/L, baseline 10.2 (13.8), 3 months 7.1 (9.8), 6 months 4.4 (3.6), 9 months 4.0 (4.2), 12 months 3.4 (4.1), ns.	Dry body weight: kg, baseline 70.9 (20.2), 3 months 71.0 (21), 6 months 71.2 (20.5), 9 months 71.6 (19.5) [1], 12 months 72.1 (19.8) [1] P= 0.04. BMI: kg/m ² , baseline 22.8 (5.1), 3 months 22.9 (5.1), 6 months 23.2 (5.2), 9 months 23.4 (5.0) [1], 12 months 23.6 (4.9) [1] P= 0.009. Phase angle: Degrees, baseline 6.2 (1.1), 6 months 6.91 (0.73) [1], 12 months 6.88 (0.72) [2], P=0.001 ECM/BCM: Mean (± SD) baseline 0.91 (0.16), 6 months 0.78 (0.09) [1], 12 months 0.78 (0.1) [1] P= 0.002		Improvement in nutritional control.	

Demirci,	Serum albumin: g/dL, NHD baseline 3.93	Dry lean mass: Change in kg, NHD baseline 12.2 (4.1),		In-centre NHD	
2013	(0.22), after 12 months 4.14 (0.31) change 0.19	after 12 months 12.7 (4.1), change 0.5 (1.2), CHD baseline		improves nutritional	
	(0.21), CHD baseline 3.95 (0.26), after 12	11.5 (3.9), after 12 months 11.4 (3.9), change -0.1 (0.9),		status and facilitates	
	months 3.92 (0.27), change -0.02 (0.2),	between group comparison (95% CI) 0.5 (0.1; 0.9) Δ [3]		volume control.	
	between group comparison (95% CI) 0.2 (0.1;	(95% CI) 0.58 (0.17; 0.9), P=0.006			
	0.29 , Δ [3] (95% CI) 0.19 (0.1; 0.29) P=	Fat mass: Change in kg, NHD baseline 16.3 (8.7), after 12			
	<0.001	months 17.4 (8.4), change 1.1 (2.5), CHD baseline 16.5			
	CRP: mg/dl, NHD baseline 1.67 (2.01), 12	(7.7), after 12 months 16.1 (7.6), change -0.4 (3.2),			
	months 1.32 (1.27), change -0.34 (1.26), CHD	between group comparison (95% CI) 1.5 (0.4; 2.7) Δ [3]			
	mg/dl, mean (± SD) baseline 1.53 (1.46), 12	(95% CI) 1.8 (0.8; 2.7), P<0.001			
	months 1.65 (1.61), change 0.1 (1.6) Between	Phase angle: Change in phase angle degrees, NHD			
	group comparison (95% CI) baseline 0.14 (-	baseline 6.32 (1.01), after 12 months 6.39 (1.38), change			
	0.54; 0.82), 12 months -0.33 (-0.88; 0.18),	0.06 (1.05), CHD baseline 6.01 (1.13), after 12 months 5.71			
	change 0.45 (-1.03; 0.1) Δ (95% CI) -0.35	(1.33), change -0.29 (0.9) , between group comparison $(95%)$			
	(0.81; 0.1) P = 0.12	CI) 0.35 (-0.02; 0.74) Δ [3] (95% CI) 0.37 (0.01; 0.7)			
		ECW/weight : Change in $1/\text{kg}$, NHD baseline 0.26 (0.03),			
		after 12 months 0.25 (0.03) , change -0.01 (0.02) , CHD			
		baseline 0.26 (0.02), after 12 months 0.26 (0.01), change $0.01 (0.02)$, between severe severes (0.5% CI), 0.01 (
		0.01 (0.9), between group comparison (95% C1) -0.01 (-			
		CW/baight: Change in 1/m NHD baseline 10.22 (1.02)			
		EC w/neight. Change in 1/11, NHD baseline $10.22 (1.05)$, after 12 months 0.07 (1.12) shange 0.25 (0.8) CHD			
		and 12 months $9.97 (1.12)$, change $-0.23 (0.0)$, CHD baseline 10 21 (1.43) after 12 months 10 46 (1.33) change			
		$0.25 (0.7)$ between group comparison (95% CI) $_{-}0.5 (-0.8)$			
		(0.25)(0.7), between group comparison (95% CI) $(0.5)(-0.8)(-0.22) \Delta [3] (95% CI) (-0.44)(-0.68)(-0.20) P < 0.001$			
Inoma 2012	PCP : g/day, baseling CHD 80 (27) 4 months	BMI: kg/m ² baseline CHD 26 1 (4.8). 4 months NHHD	Energy inteke: Kcal/day, baseline	The transition from	After the transition
ipenia, 2012	NHHD 94 (22) 8 months NHHD 96 (20)	26.2 (5.0) 8 months NHHD 26.6 (5.3) P=0.138 [4]	CHD 2003 (287) 4 months NHHD	CHD to NHHD has a	to NHD the first
	P=0.001. Effect size (95% CI for difference	Post-dialvsis weight: kg, baseline CHD 83.4 (16.8), 4	2166 (298), 8 months NHHD 2183	positive effect on	measurement was
	with baseline CHD). $P < 0.05, 0.4$ months 4.7:	months NHHD 83.6 (17.1). 8 months NHHD 84.8 (17.8)	(388) P=0.088 [4]	nutritional intake, in	done after 4 months
	24.7 g/day, 0-8 months 5.3; 27.0 g/day	P=0.183 [4]	Protein intake: g/day, baseline CHD	particular, protein	of NHD: the second
	nPCR: g/kg/day, baseline CHD 1.07 (0.27), 4	MUAMC: cm, baseline CHD 27.0 (4.2), 4 months NHHD	80 (11), 4 months NHHD 92 (19), 8	intake.	measurement was
	months NHHD 1.29 (0.22), 8 months NHHD	27.4 (4.4), 8 months NHHD 27.4 (4.1) P=0.392 [4]	months NHHD 89 (19) P=0.023 Effect		done after 8 months
	1.30 (0.19) P=0.001 [2] Effect size (95% CI for	Interdialytic weight: Change in kg/24 hours, baseline	size (95% CI for difference with		NHD.
	difference with baseline CHD),P<0.05, 0-4	CHD 1.2 (0.7), 4 months NHHD 1.5 (0.6), 8 months	baseline CHD) 0-4 months 0.2; 22.8		
	months 0.04; 0.4 g/day, 0-8 months 0.4; 4.14	NHHD 1.7 (0.6) P=0.034 [5] Effect size (95% CI for	g/day, P<0.05, 0-8 months -4.3; 21.0		
	g/day	difference with baseline CHD) [6] 0-4 months -0.3; 0.9	g/day		
	Serum albumin: g/L, baseline CHD 38 (4.0), 4	kg/24 hours, 0-8 months 0.02; 1.1 kg/24 hours, P<0.05	Carbohydrate intake: g/day, baseline		
	months NHHD 40 (3.4), 8 months NHHD 40		CHD 236 (44), 4 months NHHD 237		
	(4.1) P=0.232 [4]		(36), 8 months NHHD 252 (46)		
			P=0.369 [4]		
			Fat intake: g/day, baseline CHD 82		
			(17), 4 months NHHD 91 (24), 8		
IZ IZ		D at 12 Let and 14 D '1 T' 12 11 1 1'	months NHHD 91 (29) P=0.103 [4]		
Kaysen,	Serum albumin: Daily Trial 3xweek g/dL,	Post-dialysis weight: Daily Trial 3x week kg, baseline		Frequent nocturnal	For good
2012	baseline $3.95 (0.44)$, 4 months $3.94 (0.4)$, 12 months $3.96 (0.4)$ [6] Change from baseline 4	(10.86) [6] Change from baseline 4 menths (0.27) (0.28) 12		nemodialysis yielded	comparison we only
	months $0.02(0.02)$ 12 months 0.00	(17.00) [0] Change from baseline 4 months 0.57 (0.28), 12 months 0.22 (0.45) Nosturnal Trial 2y work has baseline		no net effect on	trial the 2 times
	(0.03)Nocturnal Trial 3xweek g/dL baseline	83 45 (24 08) 4 months 83 3 (25 03) 12 months 84 05		nutritional status or	weekly sessions and

	3.93 (0.53), 4 months 4.1 (0.45), 12 months	(25.64) [6] Change from baseline 4 months -0.44 (0.45), 12	body composition.	not the daily HD of
	4.12 (0.39) [6] Change from baseline 4 months	months 0.36 (0.79) Nocturnal Trial 6x week kg, baseline		6 times per week.
	0.17 (0.05), 12 months 0.20 (0.05) Nocturnal	88.55 (28.19), 4 months 87.8 (28.56), 12 months 89.07		The nPCR was not
	Trial 6xweek g/dL, baseline 3.88 (0.49), 4	(28.56) [6] Change from baseline 4 months -0.45 (0.44), 12		shown in the
	months 4.1 (0.49), 12 months 4.08 (0.53) [6]	months 0.88 (0.78)Treatment comparison 6x vs. 3x, 4		original article, but
	Change from baseline 4 months 0.2 (0.05), 12	months -0.02 (-1.25; 1.22) P=0.98, 12 months 0.51 (-1.66;		delivered after
	months 0.19 (0.05)Treatment comparison 6x	2.69) P=0.64		questioning for
	vs. 3x, 4 months 0.03 (-0.10; 0.16) P=0.65, 12	Phase angle: Daily Trial 3xweek degrees, baseline 5.21		them.
	months -0.01 (-0.14; 0.12), P=0.88	(1.21), 4 months 5.32 (1.44), 12 months 5.34 (1.58) [6]		
	ePCR: Daily Trial 3xweek g/day, baseline	Change from baseline 4 months 0.01 (0.13), 12 months -		
	64.67 (17.86), 4 months 65.09 (19.09), 12	0.02 (0.15)Nocturnal Trial 3x week degrees, baseline 5.54		
	months 64.26 (20.02) [6] Change from baseline	(1.48), 4 months 5.76 (1.48), 12 months 5.98 (1.66) [6]		
	4 months 0.03 (1.19), 12 months -0.35	Change from baseline 4 months 0.16 (0.24), 12 months		
	(1.29)Nocturnal Trial 3xweek g/day, mean (±	0.37 (0.22) Nocturnal Trial 6x week degrees, baseline 5.49		
	SD) baseline 62.42 (21.6), 4 months 63.28	(1.51), 4 months 5.81 (1.69), 12 months 5.79 (1.67) [6]		
	(21.49), 12 months 69.97 (24.23) [6] Change	Change from baseline 4 months 0.25 (0.24), 12 months		
	from baseline 4 months 1.65 (3.24), 12 months	0.32 (0.23). Treatment comparison 6x vs. 3x, 4 months		
	6.3 (3.33) Nocturnal Trial 6x week g/day,	0.09 (-0.53; 0.72) P= 0.77, 12 months -0.05 (-0.66; 0.56)		
	baseline 62.86 (21.15), 4 months 70.96	P=0.87		
	(22.05), 12 months 74.55 (38.81) [6] Change	Lean body mass: Daily Trial 3xweek kg, baseline 44.0		
	from baseline 4 months 7.41 (3.24), 12 months	(10.2), 4 months 44.2 (9.7), 12 months 45.0 (9.6) [6]		
	11.94 (3.45)Treatment comparison 6x vs. 3x, 4	Change from baseline 4 months 0.53 (0.26), 12 months		
	months 5.76 (-2.42; 13.94) P=0.17, 12 months	0.58 (0.32) Nocturnal Trial 3x week kg, baseline 46.3		
	5.65 (-2.98; 14.27) P=0.20	(11.7), 4 months 46.1 (11.5), 12 months 44.8 (11.4) [6]		
		Change from baseline 4 months -0.23 (0.41), 12 months -		
		0.04 (0.61) Nocturnal Trial 6x week kg, baseline 47.4		
		(12.5), 4 months 47.2 (12.2), 12 months 48.2 (12.0) [6]		
		Change from baseline 4 months -1.34 (0.41), 12 months -		
		0.49 (0.63)Treatment comparison 6x vs. 3x, 4 months -1.11		
		(-2.25; 0.04) P= 0.057, 12 months -0.45 (-2.18; 1.28)		
		P=0.61		
		% Adiposity: Daily Trial 3xweek kg, baseline 37.6 (13.7),		
		4 months 36.8 (13.4), 12 months 37.3 (12.8) [6] Change		
		from baseline 4 months -0.23 (0.29), 12 months -0.09		
		(0.41) Nocturnal Trial 3x week kg, baseline 37.9 (14.6), 4		
		months 37.7 (14.5), 12 months 37.5 (15.1) [6] Change from		
		baseline 4 months -0.53 (0.57), 12 months -0.17 (0.81)		
		Nocturnal Trial 6x week kg, baseline 40.9 (17.7), 4 months		
		42.5 (18.1), 12 months 44.4 (18.5) [6] Change from		
		baseline 4 months 0.25 (0.56), 12 months 1.73 (0.82)		
		Treatment comparison 6x vs. 3x, 4 months 0.78 (-0.78;		
		2.35) P= 0.32, 12 months 1.90 (-0.36; 4.17) P=0.10		
		TBW, ECW, ICW and BCM: no significant changes in		
		the NHD groups.		
Maduel,	nPCR: g/kg/day, all patients: baseline 1.24	Body weight: kg, all patients: baseline 70.1 (19), 3 months	Nocturnal every-	Not suitable for the
20111	(0.4), 3 months 1.40 (0.5), 6 months 1.44 (0.6),	70.6 (19), 6 months 71.3 (19) (P<0.05), 9 months 71.7(19)	other-day OL-HDF	meta-analysis
	9 months 1.44 (0.7), 12 months 1.36 (0.7)	(P<0.01), 12 months 72.2 (19) (P<0.01)	could be a good	because online HDF
	Albumin: mg/dL all patients: baseline 3.98	Weight gain: kg, all patients: baseline 2.62 (1.1), 3 months	alternative since also	during NHD was
	(0.4), 3 months 3.93 (0.3), 6 months 3.92 (0.3),	3.24 (1.2), 6 months 2.95 (1.0), 9 months 3.17 (1.5), 12	improvement in	used.
	9 months 3.88 (0.2), 12 months 3,90(0.3)	months 3.33 (1.4)	nutritional status was	

	CRP: mg/L, all patients: baseline 0.97 (1.6), 3			observed.	
	months $0.98(1.3)$, 6 months $0.69(0.8)$, 9				
McPhatter, 1999 O'Sullivan, 1998	Serum albumin: mg/dL, (mean, SD not available): 6 months before NHHD 3.4, 6 months after start NHHD 4.1 Serum albumin: g/dL, pre-study 3.63 (0.52), study period 3.68 (0.41), post-study 4.00 (0.26) Pre-study vs. NHD P<0.10 Post-study vs. NHD P>0.10 PCR: g/kg/day pre-study 1.07 (0.12) study	 Body weight: Weight gain of 2% to 3% in the first year. No data shown. Body weight: Not significant. No data shown. 	Energy intake: Kcal/day, (mean, SD not available), baseline 1801 (1208; 2777), 3 months 2045 (1454; 2654), 6 months 2150 (1721; 3120) Protein intake: g/day, (mean, SD not available), baseline 76 (45 to 107), 3 months 87 (56 to 107), 6 months 80 (56 to 113) Energy intake: Kcal/day,pre-study 2223.33 (1024.04) vs. study period 2628.33 (928.09) P=0.029	NHHD patients show healthy eating, adequate kilocalorie and protein intake, and maintaining dry weight and protein stores. Higher doses of hemodialysis benefit nutrition, improve biochemical variables, and may improve	The results are not shown all in numbers, but in figures. The standard deviations are not given and in the figures it is not clear whether the standard deviation is used. Very low amount of participants, 4 patients. The study time was only 8 weeks
	period 1.27 (0.20), post-study 1.07 (0.12), study period 1.27 (0.20), post-study 1.19 (0.26) Pre-study vs. NHD P=0.075 Post-study vs. NHD P>0.10			many hormonal systems.	weeks.
Pierratos, 1997	Serum albumin: g/L, pre-study CHD 41.2 (2.6), study period NHD 41.4 (2.7)	Body weight: Overall increase by 1.0±3.0 kg in 12 months (ns). No data shown.	Protein intake: within the first 6 months from 59 (18) to 86 (13) in g/day P=0.004, or 1.0 (0.3) to 1.44 (0.2) in g/kg/day P=0.009 Energy intake: Kcal/day, before conversion to NHD 1550 (670) to 1800 (360) at 6 m after conversion (ns)	An increase in the protein intake was found on nocturnal hemodialysis. Some of the patients gained significant weight (up to 5.5 kg).	The exact data of the body weight was not shown.
Schorr, 2011	For subjects completing food diaries: (NHD $n = 12$, CHD $n = 11$) Serum albumin: g/L, NHD baseline 37.1 (4.4), 6 months 37.8 (4.0). CHD baseline 36.6 (3.5), 6 months 35.0 (3.5), change from baseline to exit: 0.7 (3.6) NHD (n=12), -1.6 (4.0) CHD (n=11), between group comparison (95% Cl): 2.3 (-0.97; 5.6) For all study subjects: $n=51$ (NHD $n=26$, CHD $n=25$) Serum albumin: g/L, NHD baseline 36.6 (4.7), 6 months 36.4 (5.3) CHD baseline 36.0 (3.6), 6 months 35.9 (3.7), change from baseline to exit: -0.2 (4.5) on NHD, -0.2 (4.1) on CHD. Between group comparison (95% Cl): 0.0 (-2.4; 2.4)	For subjects completing food diaries: (NHD $n=12$, CHD $n=11$) For all study subjects: $n=51$ (NHD $n=26$, CHD $n=25$) Weight: kg, NHD baseline 80.0 (17.2), 6 months 80.2 (17.6), CHD baseline 69.3 (19.4), 6 months 69.0 (18.1), change from baseline to exit: 0.1 (3.3) on NHD, -0.3 (2.8) on CHD, between group comparison (95% Cl): 0.5 (-1.3; 2.2) BMI: kg/m ² , NHD baseline 27.3 (6.7), 6 months 27.4 (6.9), CHD baseline 23.5 (5.5), 6 months 23.4 (5.0), change from baseline to exit: 0.05 (1.14) on NHD, -0.12 (0.96) on CHD, between group comparison (95% Cl): 0.17 (-0.43; 0.76)	For subjects completing food diaries: (NHD $n=12$, CHD $n=11$) Carbohydrate intake: g/day, median (IQR) change from baseline to exit: - 17.7 (-56.9; 53.1) on NHD, 9.7 (-56.9; 53.7) on CHD. Between group comparison (95% Cl) P=0.81 Protein intake: g/kg/day, median (IQR) change from baseline to exit: -0.07 (-0.13; 0.21) on NHD, 0.07 (-0.15; 0.44) on CHD. Between group comparison (95% Cl) P=0.67 Fat intake: g/day, median (IQR) change from baseline to exit: 4.3 (-23.7; 36.9) on NHD, -4.0 (-11.2; 17.6) on CHD. Between group comparison (95% Cl) ns. For all study subjects: $n=51$ (NHD n=26, CHD $n=25$)	NHD subjects demonstrated a small increase in weight and BMI. Whether these dietary changes translate to improvements in nutritional status remains to be determined.	The results of the food records are not used in the meta analysis because the results are shown in median (IQR).

Sikkes,	nPCR: g/kg, baseline 1.1 (0.1), 3 months 1.6	Body weight: kg, baseline 71 (4), 3 months 74 (4), 6	Energy intake: kcal/day, baseline 2083	Nocturnal home	In the article not
2009	(0.1), 6 months 1.6 (0.1), 12 months 1.5 (0.1)	months 74 (4), 12 months 76 (5) P=0.001	(119), 3 months 2305 (132), 6 months	hemodialysis results	mean ±SD were
	P= 0.058	BMI: kg/m ² , baseline 22 (1), 3 months 23 (1), 6 months 23	2282 (131), 12 months 2213 (159)	in improved appetite	used, but the
	Serum albumin: g/L, baseline 40 (1), 3 months	(1), 12 months 24 (1) P=0.001	P=0.220	and better nutritional	mean±SE. The SE
	43 (0), 6 months 43 (1), 12 months 42 (1) P=		Protein intake: g/kg, baseline 1.1	status, with	was rounded. The
	0.001		(0.1), 3 months 1.3 (0.1), 6 months 1.3	potentially positive	authors send us the
			(0.1), 12 months 1.3 (0.1) P= 0.024	effect on morbidity	not-rounded
			Protein intake in g/day, baseline 74	and mortality,	numbers and we
			(4), 3 months 90 (6), 6 months 93 (6),	although this has not	were able to
			12 months 92 (6) P=0.003	been proven in a	compute the SE to
			Carbohydrate intake: g/day, baseline	randomized study.	the SD by using:
			263 (17), 3 months 287 (20), 6 months		$(SE = SD/\sqrt{n})$
			262 (18), 12 months 249 (18) P=0.318		
			Fat intake: g/day, baseline 79 (6), 3		
			months 85 (6), 6 months 90 (7), 12		
			months 89 (9) P=0.123		
Spanner,	nPNA:NHD patients g/kg/day, (number of	Mean arm muscle area: Nocturnal HD patients values in	Energy intake: Food intake remained	Increased nPNA,	This study
2003	patients) baseline 1.03 (0.21) (12), 3 months	cm ² , (number of patients) baseline 45.83 (11.53) (11), 3	unchanged, with a trend toward	serum albumin levels,	compared daily HD
	1.15 (0.27) (7), 6 months 1.09 (0.30) (8), 9	months 45.85 (12.07) (10), 6 months 47.29 (11.66) (8), 9	improved kilojoule ingestion in daily	and arm muscle area	and NHD with a
	months 1.14 (0.31) (10), 12 months 1.16 (0.45)	months 43.33 (10.56) (6), 12 months 43.80 (10.64) (5),	HD patient, but not significant P=0.126	suggest that daily HD	control group on
	(8), CHD patients g/kg/day, (number of	Fat mass: The daily HD and nocturnal HD groups did not	(no data shown)	patients experienced	CHD. The results of
	patients) baseline 1.02 ± 0.22 (22), 3 months	show significant differences, they remained 32% or greater		improved nutritional	the daily HD are not
	1.02 (0.16) (21), 6 months 1.05 (0.21) (17), 9	for daily HD patients, and 36% or greater for nocturnal HD		status. (No	shown in this
	months 1.07 (0.23) (18), 12 months 1.12 (0.30)	patients (no data shown)		conclusions of NHD)	systematic review.
	(20), Serum albumin: Nocturnal HD patients	BMI: No significant changes. Mean BMI's for daily HD			
	g/dL, (number of patients) baseline 3.91 (0.44)	was \geq 27, nocturnal HD \geq 23, and control HD patients \geq 26			
	(13), 3 months 3.84 (0.46) (12), 6 months 3.92	RBW: Daily HD patients maintained 100% to 110%% of			
	(0.66) (13) , 9 months 3.60 (0.58) [7] (10) , 12	RBW, nocturnal HD patients showed a significant decline			
	months 3.70 (0.52) (9), Control group CHD	in RBW after 9 months. By that point in the study, their			
	patients g/dL(number of patients) baseline 3.74	values approached 80% of RBW, indicating a significant			
	(0.4) (21), 3 months 3.76 (0.45) (19), 6 months	decline (no data shown)			
	3.77 (0.45) (20), 9 months 3.81 (0.39) (21), 12				
	months 3.81 (0.41) (20)				

All figures are shown in mean (± standard deviation), unless stated otherwise.

Abbreviations: PCR: protein catabolic rate, nPCR: normalized protein catabolic rate, CRP: C-reactive protein, BMI: body mass index, ECW: extracellular water, ICW: intracellular water, MUAMC: mid upper arm muscle circumference, % adiposity: fat mass, TBW: total body water, ICW: intracellular water, BCM: body cell mass, nPNA: normalized protein nitrogen appearance, IQR: inter quartile range, RBW: relative body weight.

[1] P < 0.01 compared to baseline.

[2] P < 0.0001 compared to baseline.

[3] Adjusted for age, gender, presence or absence of diabetes, BMI, dialysis duration, center effect and the baseline level of the factor analyzed.

[4] Repeated-measures analyses comparing baseline CHD with 4 and 8 months of NHHD.

[5] The effect size is showed only for parameters that changed significantly in the repeated-measures analysis.

[6] Adjusted means and treatments effects. Adjusted means and treatment effects were estimated under mixed-effects models with adjustment for the baseline level of the outcome and clinical center in the Daily

Trail, and the baseline level of the outcome in the Nocturnal Trial (\pm s.e. or with 95% confidence interval).

[7] $P = \langle 0.05 \text{ for indicated value versus baseline at that time.}$